Femasys Announces Public Offering to Enhance Women’s Health
Femasys Inc. (NASDAQ: FEMY), a pioneering biomedical firm dedicated to addressing crucial unmet health needs in women, has announced an impressive underwritten public offering of common stock. The company, renowned for its innovative in-office therapeutic and diagnostic products, has set the offering at 10,434,586 shares. In addition, pre-funded warrants are available to purchase up to 11,750,000 shares, complemented by accompanying common warrants for a maximum total of 22,184,586 shares.
Offering Pricing Details
The public offering price is set at $0.36 per share for most investors, while 87,363 shares intended for certain company officers are priced slightly higher at $0.5151 per share. The offering also includes pre-funded warrants priced at $0.3599, with each warrant immediately exercisable upon issuance and remaining valid for five years. This strategic financial maneuver aims to generate approximately $8.0 million for Femasys, providing support for their expansive commercial initiatives and product developments.
Utilization of Proceeds
The company plans to allocate the net proceeds from this offering to crucial areas such as enhancing its commercial efforts, product development, and general corporate purposes, along with important capital expenditures and administrative costs. All shares are being sold from the company’s treasury, ensuring the funding aligns with its growth objectives.
Management of the Offering
Jones and Laidlaw & Company (UK) Ltd. have taken the role of joint book-running managers for this offering, providing valuable support in managing the offering structure and execution.
Femasys’ Commitment to Innovation
Femasys is at the forefront of making fertility treatments and non-invasive permanent birth control solutions more accessible and affordable. The company’s remarkable portfolio includes patented products designed to be used in-office, tackling the significant issues surrounding women’s reproductive health. FemaSeed, their leading fertility innovation, stands out for its remarkably high effectiveness, particularly in treating infertility challenges.
Fertility Products and Clinical Innovations
The company’s dedication is further highlighted by their FemVue diagnostic tool, used to assess fallopian tube health, which works synergistically with FemaSeed. Their effectiveness has been demonstrated through clinical studies, showcasing that FemaSeed procedures are over twice as effective as traditional intrauterine insemination (IUI) methods.
Advancements in Permanent Birth Control
In the realm of permanent birth control, Femasys is revolutionizing the landscape with FemBloc, a pioneering non-surgical option that has received full regulatory approval in Europe and the UK. This innovative solution represents a significant shift from traditional surgical sterilization techniques, providing a less invasive, safer alternative. By forging strategic partnerships in chosen European markets, Femasys plans to roll out this product effectively, complementing it with the FemChec diagnostic system, which ensures confirmation of procedural success.
Ongoing Clinical Trials and Future Prospects
In pursuit of FDA approval for FemBloc in the U.S., Femasys is currently enrolling patients in the pivotal FINALE trial (NCT05977751). This trial is critical in demonstrating the product's safety and efficacy, thereby broadening the company’s product offerings to meet diverse women’s health needs.
Contact and Investor Information
For further inquiries regarding the offering and Femasys' innovative strategies in bettering women's health, interested parties can reach out via email:
Investors:
IR@femasys.com
Media Contact:
Media@femasys.com
Frequently Asked Questions
What is the primary goal of the Femasys public offering?
The public offering aims to raise funds to enhance commercial efforts, develop products, and support general corporate costs.
How many shares are involved in the Femasys offering?
The offering includes 10,434,586 shares of common stock and up to 11,750,000 pre-funded warrants.
What innovative products does Femasys offer?
Femasys offers products aimed at improving fertility treatment and permanent birth control options, including FemaSeed and FemBloc.
What are the future plans for FemBloc?
The company is pursuing FDA approval for FemBloc while also expanding its commercialization efforts in Europe.
Who is managing the Femasys offering?
Jones and Laidlaw & Company (UK) Ltd. serve as the joint book-running managers for this offering.
